Antipsychotics use in dementia: How safe are they?
European Psychiatry, 2021 Introduction Antipsychotics are frequently used for managing psychiatric and behavioral symptoms of dementia. However, it’s an off-label resource which remains controversial due to significant safety concerns in the elderly population, namely ...
C. Lopes
doaj +1 more source
Torsadogenic risk of antipsychotics : combining adverse event reports with drug utilization data across Europe [PDF]
, 2013 Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (
Barbui, Corrado +62 more
core +1 more source
BMC Psychiatry, 2009 Background Although much progress has been made on antipsychotic drug development, precise mechanisms behind the action of typical and atypical antipsychotics are poorly understood.
Song Jonathan +7 more
doaj +1 more source
Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database. [PDF]
, 2013 Objective. Assess risk of cardiac events and mortality among users of olanzapine and other antipsychotics relative to nonusers. Methods. The General Practice Research Database was used to identify cohorts of antipsychotic users and nonusers with ...
Van Staa, Tjeerd; id_orcid +8 more
core +1 more source
Antipsychotics and Amotivation [PDF]
Neuropsychopharmacology, 2015 Antipsychotic drugs are thought to produce secondary negative symptoms, which can also exacerbate primary negative symptoms. In the present study, we examined whether motivational deficits in particular were related to antipsychotic treatment in patients with schizophrenia in a dose-dependent manner.
Gagan, Fervaha +6 more
openaire +2 more sources
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis – results to be interpreted with caution [PDF]
, 2010 Randomized, controlled trials have demonstrated efficacy for second-generation antipsychotics in the treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar disorder, there are no published systematic ...
Goikolea, José Manuel +7 more
core +1 more source
Hyperprolactinemia as a side effect of using antipsychotics In Schizophrenic Patients
Jurnal Psikiatri Surabaya, 2023 Introductions: Antipsychotics are still the mainstay of schizophrenia management. Antipsychotics are antagonistic to postsynaptic dopamine receptors in the brain.
Syaiful Anwar, Khairina
doaj +1 more source
Second-generation antipsychotics and metabolic syndrome: a role for mitochondria
, 2023 Psychosis is a known risk factor for developing metabolic syndrome (MetS). The risk is even greater in patients who are taking second-generation antipsychotics (SGAs).
Mortimer, Katherine R H +2 more
core +1 more source
Focus, 2020 Physicians who treat patients with schizophrenia frequently encounter complex clinical situations not fully addressed by published treatment guidelines. Some of these situations lead to antipsychotic polypharmacy, often prescribed when clinical and social obstacles prevent access to clozapine and patients have had suboptimal responses to nonclozapine ...
Adriana, Foster, Jordanne, King
openaire +3 more sources
Comparison of relapse rates of depot and oral antipsychotics in patients with schizophrenia [PDF]
, 2017 Introduction: Antipsychotics are the mainstay of treatment in schizophrenia. First-generation and second-generation antipsychotics are available as oral and depot formulations.
Morrissey, Hana +4 more
core +1 more source